Results 101 to 110 of about 8,137,007 (226)
TOMM20 increases cancer aggressiveness by maintaining a reduced state with increased NADH and NADPH levels, oxidative phosphorylation (OXPHOS), and apoptosis resistance while reducing reactive oxygen species (ROS) levels. Conversely, CRISPR‐Cas9 knockdown of TOMM20 alters these cancer‐aggressive traits.
Ranakul Islam+9 more
wiley +1 more source
Improving precision instrument cleaning with a quality control module: implementation and outcomes. [PDF]
Xiong J+5 more
europepmc +1 more source
Presurgery 72‐h fasting in GB patients leads to adaptations of plasma lipids and polar metabolites. Fasting reduces lysophosphatidylcholines and increases free fatty acids, shifts triglycerides toward long‐chain TGs and increases branched‐chain amino acids, alpha aminobutyric acid, and uric acid.
Iris Divé+7 more
wiley +1 more source
Inter-phantom variability in digital mammography: implications for quality control. [PDF]
Gennaro G+3 more
europepmc +1 more source
Patient engagement involves actively including patients in healthcare decisions and research to ensure care and studies align with their needs. This approach improves outcomes, trust, and communication while fostering collaboration between patients and professionals.
Estela Cepeda+3 more
wiley +1 more source
Accuracy of manufacturer integrated quality control for helical radiotherapy. [PDF]
Crop F+10 more
europepmc +1 more source
Transcriptome‐wide analysis of circRNA and RBP profiles and their molecular relevance for GBM
CircRNAs are differentially expressed in glioblastoma primary tumors and might serve as therapeutic targets and diagnostic markers. The investigation of circRNA and RNA‐binding proteins (RBPs) interactions shows that distinct RBPs play a role in circRNA biogenesis and function.
Julia Latowska‐Łysiak+14 more
wiley +1 more source
The informatics pathway for hospital infection quality control monitoring. [PDF]
Wang H+7 more
europepmc +1 more source
This study investigates an alternative approach to reactivating the oncosuppressor p53 in cancer. A short peptide targeting the association of the two p53 inhibitors, MDM2 and MDM4, induces an otherwise therapeutically active p53 with unique features that promote cell death and potentially reduce toxicity towards proliferating nontumor cells.
Sonia Valentini+10 more
wiley +1 more source